ReviewThe lancet. Psychiatry2015
What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?
Review in The lancet. Psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Alzheimer's Disease is an Important Risk Factor of Fractures: a Meta-analysis of Cohort Studies.Molecular neurobiology · 2017Pooled it
- Alzheimer's drugs, APPlication for Down syndrome?Ageing research reviews · 2024Review
- Perceived risk of LSD varies with age and race: evidence from 2019 United States cross-sectional data.Social psychiatry and psychiatric epidemiology · 2023Article
- Key Characteristics and Development of Psychoceuticals: A Review.International journal of molecular sciences · 2022Review
- Understanding and Treating Niemann-Pick Type C Disease: Models Matter.International journal of molecular sciences · 2020Review
- Potential Therapeutic Approaches to Alzheimer's Disease By Bioinformatics, Cheminformatics And Predicted Adme-Tox Tools.Current neuropharmacology · 2020Review
- Does traumatic brain injury hold the key to the Alzheimer's disease puzzle?Alzheimer's & dementia : the journal of the Alzheimer's Association · 2018Review
- Drug discovery and development: Role of basic biological research.Alzheimer's & dementia (New York, N. Y.) · 2017Review
- Strategies for Utilizing Neuroimaging Biomarkers in CNS Drug Discovery and Development: CINP/JSNP Working Group Report.The international journal of neuropsychopharmacology · 2017Review
- Mild traumatic brain injury-induced hippocampal gene expressions: The identification of target cellular processes for drug development.Journal of neuroscience methods · 2016Article
- miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Drug development for psychiatric disorders has almost ground to a halt. Some newer drugs are better tolerated or safer than older ones, but none is more effective. Years of failure in preventing or delaying the onset of illness, ameliorating symptoms, lowering suicide rates, or improving quality of life has put the commercial investments that had previously funded drug development at risk. To promote the development of psychiatric drugs with greater efficacy, we need to improve the way we bring potentially beneficial drugs to market. We need to acknowledge, as has been done in other specialties, that people differ in their response to drugs. Psychiatric drug research needs to be grounded in a better understanding of molecular brain mechanisms, neural circuits, and their relations to clinical disease. With this understanding, drugs need to be more precisely directed at specific brain targets. In psychiatric drug development, government, industry, regulatory bodies, and academia should realign to ensure medical science is used in the best interests of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.